TickerFacts.

Krystal Biotech, Inc. (KRYS): Revenue

Annual figures by period end, from SEC filings.

$389.13M
Year ended 2025-12-31
$440.48M
Trailing 12 months to 2026-06-30
2021-12-31: $02022-12-31: $02023-12-31: $50.70M2024-12-31: $290.51M2025-12-31: $389.13M$389.13M
2021-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$389.13M+33.9%2026-02-17, From 2025-01-01
2024-12-31$290.51M+473.0%2026-02-17, From 2024-01-01
2023-12-31$50.70Mn/a2026-02-17, From 2023-01-01
2022-12-31$0n/a2025-02-19, From 2022-01-01
2021-12-31$0n/a2024-02-26, From 2021-01-01

Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Krystal Biotech, Inc. (KRYS)2025-12-31$389.13M+33.9%
Immunocore Holdings plc (IMCR)2025-12-31$400.02M+29.0%
Twist Bioscience Corp (TWST)2025-09-30$376.57M+20.3%
Tarsus Pharmaceuticals, Inc. (TARS)2025-12-31$451.36M+146.7%
ADMA Biologics, Inc. (ADMA)2025-12-31$510.17M+19.6%
Adaptive Biotechnologies Corp (ADPT)2025-12-31$276.98M+54.8%
Vericel Corp (VCEL)2025-12-31$276.26M+16.5%
Iovance Biotherapeutics, Inc. (IOVA)2025-12-31$263.50M+60.6%
Vaxart, Inc. (VXRT)2025-12-31$237.26M+726.7%

Compare KRYS, IMCR, TWST, TARS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗